Close
 

Figure 1: The effects of DON (5 μm), RGN (0-5 μm), or a combination thereof on the proliferation of HepG2 cells. (a) DON on HepG2 viability (0‒10 μm for 6, 12, or 24 h, respectively). (b) Cell viability effect of RGN on HepG2 (0‒5 μm for 24 h). (c) RGN protects against the cytotoxic effect of DON. (d) SDS-PAGE was done after different concentrations of DON (5 μm) or RGN (0-1) were added to cells for 24 hours. Expressions of TNFα and COX-2 were analyzed. (e) DCFH2-DA was used to measure intracellular ROS generation. Data are mean ± SD of values (n = 3), *P < 0.05 represents significant difference compared to DON alone. #P < 0.05 for RGN compared with the DON treatment groups

Figure 1: The effects of DON (5 μm), RGN (0-5 μm), or a combination thereof on the proliferation of HepG2 cells. (a) DON on HepG2 viability (0‒10 μm for 6, 12, or 24 h, respectively). (b) Cell viability effect of RGN on HepG2 (0‒5 μm for 24 h). (c) RGN protects against the cytotoxic effect of DON. (d) SDS-PAGE was done after different concentrations of DON (5 μm) or RGN (0-1) were added to cells for 24 hours. Expressions of TNFα and COX-2 were analyzed. (e) DCFH2-DA was used to measure intracellular ROS generation. Data are mean ± SD of values (<i>n</i> = 3), *<i>P</i> < 0.05 represents significant difference compared to DON alone. #<i>P</i> < 0.05 for RGN compared with the DON treatment groups